Improved QOL Considered To Be a Valid Clinical Endpoint in Itself

Improved QOL Considered To Be a Valid Clinical Endpoint in Itself

TAMPA, Florida—"Increasingly we have acknowledged that there is
more to cancer treatment than the eradication of disease," stated Paul
Jacobsen, PhD. "The treatment of anemia and its effects on quality of
life have demonstrated that a treatment can be considered effective and
clinically useful if it results in significant quality-of-life benefits,
even in the absence of significant survival benefits."

The challenge, as outlined by Dr. Jacobsen, is how to accurately measure
quality-of-life issues and incorporate them into clinical practice. Dr.
Jacobsen is program leader, psychosocial and palliative care program, at the
H. Lee Moffitt Cancer Center, and professor, department of psychology at the
University of South Florida in Tampa.

It is commonly agreed that quality of life is "a multidimensional
construct that is best measured using instruments that assess multiple
domains of functioning and well-being," Dr. Jacobsen said. "By
definition, it is a subjective phenomenon and the patient is the best judge
of his or her own quality of life."

Three quality-of-life measures are commonly used in oncology:

  • Functional Assessment of Cancer Therapy (FACT);
  • European Organization for Research and Treatment of Cancer
    Quality-Of-Life Questionnaire (EORTC QLQC-30); and
  • Linear analogue self-assessment scales (LASA).

What and When to Measure

Selection of quality-of-life measures for a study depends on the specific
research questions and the populations being studied. While frequent
assessments of quality of life would provide more complete data, constraints
on frequency include not wanting to burden patients and the financial costs
involved in collecting and compiling data.

Beneficial Uses of Data


Loading comments...
Please Wait 20 seconds or click here to close